12 citations
,
January 2016 in “Journal of clinical biochemistry and nutrition” Deferasirox combined with sorafenib reduces liver cancer risk and lessens treatment side effects.
The dog fully recovered and regrew hair after a combination of topical and oral treatments.
7 citations
,
December 2023 in “International Journal of Molecular Sciences” Forsythiaside A helps protect cells and liver from damage by reducing oxidative stress and boosting antioxidants.
3 citations
,
February 2024 in “Journal of the American Academy of Dermatology” Topical tofacitinib cream may help treat certain hair loss conditions with fewer risks.
February 2006 in “Inpharma Weekly”
7 citations
,
May 2015 in “Journal of The American Academy of Dermatology” Finasteride helps treat frontal fibrosing alopecia, improving or stabilizing the condition in many patients.
January 2025 in “International Journal of Drug Delivery Technology” A reliable method was developed to measure Finasteride and Tadalafil together, showing they degrade under certain conditions.
52 citations
,
January 2005 in “PubMed” Alpha-blockers are the most effective and widely used treatment for lower urinary tract symptoms, with minimal side effects.
January 2022 in “Essentials in ophthalmology” Tamsulosin increases the risk of floppy iris syndrome during cataract surgery.
August 2018 in “bioRxiv (Cold Spring Harbor Laboratory)” Existing drugs, including a blood pressure medication, show promise as new treatments for influenza.
January 2023 in “National journal of physiology, pharmacy and pharmacology” Low-dose methotrexate is generally safe but can cause mild to severe side effects, and folic acid can reduce these risks.
May 2024 in “Reactions weekly”
44 citations
,
April 2006 in “Expert opinion on drug safety” Gefitinib can cause skin problems, diarrhea, and nausea, but rarely causes severe lung disease or hair loss.
March 2023 in “Reactions Weekly” 7 citations
,
May 2008 in “Journal of Veterinary Internal Medicine” A cat had a rare severe reaction to fenbendazole, but recovered with treatment.
August 2007 in “Drug and therapeutics bulletin” Eflornithine's effectiveness for women with facial hirsutism is unclear.
January 2025 in “International Journal of Dermatology Venereology and Leprosy Sciences” Tofacitinib improved hair regrowth and quality of life in children with alopecia areata, with mild side effects.
4 citations
,
June 2020 in “BMC Ophthalmology” Minoxidil can cause a rare eye condition, but it was successfully treated with oral Eplerenone in one case.
9 citations
,
June 2014 in “Nutrition and Cancer” Eclipta alba extract may work as an anticancer agent and help reverse drug resistance.
January 2019 in “Actas urológicas españolas” Using mirabegron and solifenacin together is safe and more effective for treating overactive bladder than using either drug alone.
December 2013 in “Urology reports (St - Petersburg)” Sonirid Duo effectively treats benign prostatic hyperplasia.
January 2018 in “Haydarpaşa Numune Hastanesi tıp dergisi” Tamsulosin's sulfonamide group may contribute to floppy iris syndrome.
114 citations
,
December 1951 in “Archives of Dermatology” Aminopterin strongly suppresses epithelial tissues and can treat certain skin conditions but has significant side effects.
June 2025 in “Indus journal of bioscience research.” Oral tofacitinib is more effective than oral minoxidil for treating alopecia areata.
March 2002 in “Clin-Alert” In 2002, various drugs caused serious side effects, including vitamin B12 deficiency, heart issues, blindness, hypersexuality, allergic reactions, blood clotting problems, pupil dilation, capillary leak syndrome, muscle breakdown, hepatitis, skin reactions, and lupus.
2 citations
,
April 2022 in “Cutaneous and Ocular Toxicology” Tofacitinib may help treat hair loss in children with alopecia areata.
2 citations
,
July 2022 in “Frontiers in Cardiovascular Medicine” Forsythiasides have multiple health benefits but may cause pseudoallergic reactions, and more research is needed.
January 2014 in “Reactions Weekly” June 2014 in “Reactions Weekly” May 2026 in “Reactions Weekly”